• darkblurbg

    Developing therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Production Scientist with GMP experience

We welcome candidates with relevant life science experience to join our team.


 Dates for financial information and other events
Data pager
Data pager
November 5, 2020
Annual Report
Annual Report 2019/2020
November 26, 2020
Annual General Meeting
Annual General Meeting 2019/2020
January 20, 2021
Quarterly Report I
Quarterly Report 1 2020/2021
March 31, 2021
Quarterly Report II
Quarterly Report 2 2020/2021

Company Presentation

The focus forward into Phase III and beyond is aligned with genetics-based Precision Medicine - targeting the right individual with the right treatment at the right time.

Ulf Hannelius
President and CEO, Diamyd Medical AB
Financial Statement 19/20


Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research